Erasca, Inc.

The momentum for this stock is not very good. Erasca, Inc. is not very popular among insiders. Erasca, Inc. is a mediocre stock to choose.

News

Erasca Insiders Enjoying US$2.5m Appreciation On US$3.97m Investment

Simply Wall St Insiders who bought Erasca, Inc. ( NASDAQ:ERAS ) stock in the last 12 months were richly rewarded last week. The...\n more…

Erasca participates in a conference call with JPMorgan

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Erasca participates in a conference call with JPMorgan

Short Interest in Erasca, Inc. (NASDAQ:ERAS) Grows By 5.2%

Ticker Report Erasca, Inc. (NASDAQ:ERAS - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 23,420,000...\n more…

Erasca to Present at Upcoming Investor Conferences in September

Globe Newswire SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...\n more…

SG Americas Securities LLC Sells 14,107 Shares of Erasca, Inc. (NASDAQ:ERAS)

Ticker Report SG Americas Securities LLC cut its holdings in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 38.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and...\n more…